Onyx Scientific has picked-up several new clients from the US and Europe following a record year of growth for the contract research and development organization.
New drug development customers requiring chemistry synthesis services, process development, lead optimization, solid state services and small scale GMP manufacturing have helped drive investment at the company’s UK-based facility.
Over the last 12 months, Onyx Scientific has supported the scale-up of many existing client projects while introducing numerous new projects at the pre-clinical/clinical development phase.
Denise Bowser, commercial director at Onyx Scientific, said: “We’ve experienced encouraging growth over the last 18 months, mainly driven by our reputation for dealing with complex chemistry and delivering projects against challenging timelines.
“Our business has always been about delivering the highest levels of expertise and integration between development services, without the customer having to pay a premium. This is why 90% of our clients use us time and time again and also why we continue to attract new clients.”
Onyx Scientific recently completed the latest phase of its site expansion in Sunderland, increasing storage facilities & boosting capacity in terms of its capability to deal with multiple campaigns.[addtoany]